开源证券研报指出，健康元2025H1归母净利润7.85亿元（+1.10%）；公司2025H1毛利率为62.21%（-1.10pct）；净利率为22.33%（+1.73pct）。2025单Q2公司归母净利润3.49亿元（+3.72%，环比-19.88%）。公司各业务板块协同发力，丽珠集团作为发展基本盘，持续贡献稳定业绩，丽珠单抗对公司归母净利润的影响较2024H1减亏0.62亿元，公司妥布霉素2025H1销售额同比实现增长112%，呈现出良好的增长态势；保健品板块同比增长35%；原料药板块运营同样稳健，重点产品7-ACA价格维持良好态势，美罗培南原料药价格逐步止跌企稳。该行看好公司呼吸赛道的创新优势，维持2025-2027归母净利润为14.63/15.68/17.15亿元，EPS为0.80/0.86/0.94元/股，当前股价对应PE为16.1/15.0/13.7倍，维持“买入”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.